Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Elicera Therapeutics AB (8E8) Stock Price & Analysis

8E8 Stock Chart & Stats

€0.21-€0.01(-2.75%)
At close: 5:30 PM GMT+1
EUR 0.2EUR 0.4EUR 0.618 Jan17 Dec19 May31 Jul30 Sep14 May
Day’s Range
EUR 0.21 - EUR 0.22
52-Week Range
EUR 0.18 - EUR 0.59
Previous Close
EUR 0.22
Volume
0
Average Volume (3M)
0
Market Cap
EUR 16.09M
Enterprise Value
EUR 84.26M
Total Cash (Recent Filing)
EUR 58.13M
Total Debt (Recent Filing)
EUR 0
Price to Earnings (P/E)
―
Beta
0.84
Next Earnings
Nov 27, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

A debt-free balance sheet reduces financial risk and avoids interest or refinancing burdens while the company advances its development programs. This gives management greater flexibility in allocating capital toward research, clinical work, and potential partnering activities over the next several quarters.

Meaningful Capital Base

The substantial equity base provides a stronger financial foundation than a highly leveraged structure and may support continued development activity. Although losses are reducing that base, the current capital position remains a durable offset to balance-sheet risk during the company’s clinical-stage phase.

Platform-led Partnering Model

Elicera’s iTANK platform and engineered immunotherapy programs create multiple potential routes to value creation through licensing, co-development, or acquisition transactions. If development milestones are achieved, this model could provide non-product revenue opportunities and broaden commercialization resources.

Bears Say

No Current TTM Revenue

Revenue has deteriorated sharply to zero on a trailing basis, indicating that the company currently lacks a commercial revenue stream to fund operations. Until partnering proceeds, product sales, or development milestones emerge, financial performance remains highly dependent on successful pipeline advancement.

Persistent Sizable Losses

Large recurring operating and net losses show that the present business model has not yet reached profitability. Continued losses can consume equity, limit internally funded investment, and increase the importance of successful clinical development or external transactions to establish sustainable earnings.

Sustained Cash Burn

Heavy negative operating and free cash flow indicates that ongoing research and development require substantial funding without current cash generation. The declining free-cash-flow trend increases execution and financing pressure, particularly because recurring product revenue has not yet been established.

8E8 FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?
Elicera Therapeutics AB lowest stock price was €0.18 and its highest was €0.59 in the past 12 months.
What is Elicera Therapeutics AB’s market cap?
Elicera Therapeutics AB’s market cap is €16.09M.
When is Elicera Therapeutics AB’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Elicera Therapeutics AB’s earnings last quarter?
Elicera Therapeutics AB released its earnings results on Aug 28, 2026. The company reported -€0.01 earnings per share for the quarter.
Is Elicera Therapeutics AB overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Elicera Therapeutics AB pay dividends?
Elicera Therapeutics AB does not currently pay dividends.
What is Elicera Therapeutics AB’s EPS estimate?
Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elicera Therapeutics AB have?
Elicera Therapeutics AB has 66,736,374 shares outstanding.
What happened to Elicera Therapeutics AB’s price movement after its last earnings report?
Elicera Therapeutics AB reported an EPS of -€0.01 in its last earnings report. Following the earnings report the stock price went down -2.885%.
Which hedge fund is a major shareholder of Elicera Therapeutics AB?
Currently, no hedge funds are holding shares in DE:8E8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology